KIF22 in the Prognosis and Immune Biomarking of Pan-Cancer

Figure 10

The association between KIF22 and therapy outcome in different cancers. (a) The relationship between drug susceptibility and the expression, methylation, CNV of KIF22. (b) The biomarker relevance of KIF22 compared with predefined tumor immune response biomarkers in ICB subcohorts. (c) Kaplan–Meier survival curve of ICB subcohorts with different KIF22 expression levels. (d) The relevance between KIF22 expression level and response to chemotherapy in ovarian cancer, glioblastoma multiforme and breast cancer cohorts, targeted therapy in ovarian cancer cohorts, and anthracycline therapy in breast cancer cohorts.

(a)

(b)

(c)

(d)